Abstract

Abstract The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of biospecimen-based assays that use biomarkers for the detection, diagnosis, and prognosis of cancer and the assessment of response to cancer treatment. The biospecimen-based assessment modality pathway was conceived not as comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway.

Keywords

Translational researchModalitiesMedicineBioinformaticsPsychologyBiologyPathology

Affiliated Institutions

Related Publications

Publication Info

Year
2008
Type
article
Volume
14
Issue
18
Pages
5672-5677
Citations
31
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

31
OpenAlex

Cite This

Sudhir Srivastava, Joe W. Gray, Brian J. Reid et al. (2008). Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities. Clinical Cancer Research , 14 (18) , 5672-5677. https://doi.org/10.1158/1078-0432.ccr-08-1267

Identifiers

DOI
10.1158/1078-0432.ccr-08-1267